Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway.
Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland.
Scand J Rheumatol. 2023 Jan;52(1):42-50. doi: 10.1080/03009742.2021.1997436. Epub 2022 Jan 11.
To estimate the prevalence of psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and rheumatoid arthritis (RA) and the use of biologic agents in these diseases in Norway.
From the Norwegian Patient Registry (NPR), we identified as PsA, axSpA and RA patients ≥18 years those with ≥2 recorded episodes with diagnostic coding for index disease (L40.5, M07.0-M07.3 for PsA; M45, M46.0, M46.1, M46.8 and M46.9 for axSpA; M05-M06 for RA). We calculated the point prevalence of PsA, axSpA and RA as per the 1 of January 2017 in the Norwegian adult population (age ≥18). Dispensed disease-modifying antirheumatic drug (DMARD) prescriptions were obtained from the Norwegian Prescription Database and biologic DMARDs given in hospitals from the NPR.
The point prevalence of PsA, axSpA, RA, and any of these diseases in total was 0.46%, 0.41%, 0.78%, and 1.56%, respectively. Among women, the prevalence of PsA, axSpA, and RA was 0.50%, 0.37%, and 1.10%, and among men 0.43%, 0.45%, and 0.46%, respectively. In 2017, 27.3% of RA patients, 25.7% of PsA patients and 35.1% of axSpA patients used biologic DMARDs. Treatment with biologics was more frequent in younger age groups in all three diseases, and became more infrequent especially after age ≥55 years.
In Norway, the combined prevalence of PsA, axSpA, and RA was over 1.5%. Reflecting the good overall access to highly effective but costly biologic treatments, more than a fourth of these patients used biologic agents, which corresponds to over 0.4% of Norwegian adult population.
估计挪威银屑病关节炎（PsA）、中轴型脊柱关节炎（axSpA）和类风湿关节炎（RA）的患病率，以及这些疾病中生物制剂的使用情况。
我们从挪威患者登记处（NPR）中确定了年龄≥18 岁的 PsA、axSpA 和 RA 患者，这些患者至少有两次记录的疾病诊断编码（L40.5、M07.0-M07.3 用于 PsA；M45、M46.0、M46.1、M46.8 和 M46.9 用于 axSpA；M05-M06 用于 RA）。我们根据 2017 年 1 月 1 日挪威成年人口（年龄≥18 岁）计算了 PsA、axSpA 和 RA 的时点患病率。从挪威处方数据库获得了疾病修正抗风湿药物（DMARD）的处方，从 NPR 获得了医院开具的生物 DMARD。
PsA、axSpA、RA 和所有这些疾病的时点患病率分别为 0.46%、0.41%、0.78%和 1.56%。女性中 PsA、axSpA 和 RA 的患病率分别为 0.50%、0.37%和 1.10%，男性分别为 0.43%、0.45%和 0.46%。2017 年，27.3%的 RA 患者、25.7%的 PsA 患者和 35.1%的 axSpA 患者使用了生物 DMARD。在所有三种疾病中，年轻患者组使用生物制剂的比例更高，尤其是在年龄≥55 岁后，使用生物制剂的比例明显下降。
在挪威，PsA、axSpA 和 RA 的合并患病率超过 1.5%。反映出整体获得高效但昂贵的生物治疗的情况良好，超过四分之一的患者使用了生物制剂，相当于挪威成年人口的 0.4%以上。
